http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013102373-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2011-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013102373-A |
| titleOfInvention | EXTENSION OF SURVIVAL WITHOUT PROGRESSION OF DISEASE WITH 10-PROPARGIL-10-DEAZAAMINOTERIN |
| abstract | 1. A method of reversing the developmental trend of progressive resistance to sequential courses of treatment of T-cell lymphoma in a patient, comprising: selecting a patient with T-cell lymphoma, where the patient has undergone at least one previous course of treatment of T-cell lymphoma, and at least one previous the course of treatment includes treatment without the use of 10-propargyl-10-deazaminopterin; and administering to the patient a composition containing a therapeutically effective amount of 10-propargyl-10-deazaminopterin to reverse the tendency of progressive resistance. 2. The method according to claim 1, characterized in that the tendency of reversing resistance to sequential courses of treatment of T-cell lymphoma in a patient is measured as the increase in the number of days of patient survival without disease progression when treated with a composition containing 10-propargyl-10-deazaminopterin, compared to the number of days of patient survival without disease progression in the immediately preceding treatment without the use of 10-propargyl-10-deazaminopterin. 3. The method according to claim 1, characterized in that 10-propargyl-10-deazaaminopterin essentially does not contain 10-deazaaminopterin. The method according to claim 1, characterized in that the T-cell lymphoma is a peripheral T-cell lymphoma. The method according to claim 1, characterized in that the T-cell lymphoma is a T-cell lymphoma of the skin. The method according to claim 1, characterized in that the T-cell lymphoma is a T-cell subcutaneous panniculitis-like lymphoma. The method according to claim 1, characterized in that the T-cell lymphoma is c� |
| priorityDate | 2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.